Day One Biopharmaceutical... (DAWN)

AI Score

Unlock

7.14

0.30 (4.39%)

At close: Apr 21, 2025, 3:59 PM

6.73

-5.74%

Pre-market: Apr 22, 2025, 04:27 AM EDT

Day One Biopharmaceuticals Income Statement

Financials in USD. Fiscal year is January - December.

Fiscal Year	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021	Q2 2021	Q1 2021	Q4 2020	Q3 2020	Q2 2020	Q1 2020
Period Ending	Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Revenue	29.21M	93.76M	8.19M	n/a	560K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost of Revenue	2.98M	1.59M	707K	116K	280K	99K	92K	89K	180K	165K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Gross Profit	26.23M	92.17M	7.49M	-116K	280K	-99K	-92K	-89K	-180K	-165K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Operating Income	-65.33M	29.64M	-114.81M	-66.77M	-59.52M	-51.44M	-49.25M	-45.85M	-42.74M	-39.7M	-36.72M	-27.75M	-121.93M	-19.24M	-15.44M	-16.09M	-6.14M	-3.56M	-2.31M	-1.77M
Interest Income	n/a	n/a	3.96M	n/a	n/a	5.29M	3.41M	n/a	2.66M	1.9M	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Pretax Income	-59.24M	36.16M	-2.85M	-62.41M	-54.51M	-46.15M	-45.86M	-42.39M	-40.11M	-37.8M	-36.53M	-27.75M	-119.83M	-19.24M	-15.47M	-16.1M	-35.6M	-3.84M	-2.41M	-1.99M
Net Income	-65.71M	37.04M	-4.41M	-62.41M	-54.51M	-46.15M	-45.86M	-35.38M	-34.81M	-34M	-36.53M	-27.74M	-119.83M	-19.24M	-14.28M	-15.18M	-34.38M	-2.82M	-1.76M	-1.53M
Selling & General & Admin	29.73M	28.97M	30.19M	26.44M	22.17M	18.27M	17.07M	18.03M	16.72M	17.66M	14.16M	12.74M	29.16M	9.39M	5.53M	3.45M	1.98M	1.02M	872K	808K
Research & Development	61.82M	33.56M	92.11M	40.21M	37.35M	33.16M	32.18M	27.83M	26.02M	22.04M	22.56M	15M	43.58M	9.85M	9.91M	12.63M	4.17M	2.54M	1.44M	961K
Other Expenses	n/a	n/a	107.99M	-10K	-18K	-3K	-15K	-4K	-26K	9K	n/a	-1K	14K	7K	-27K	-8K	-26K	-1K	-90K	-2K
Operating Expenses	91.56M	62.53M	122.29M	66.65M	59.52M	51.44M	49.25M	45.85M	42.74M	39.7M	36.72M	27.75M	72.74M	19.24M	15.44M	16.09M	6.14M	3.56M	2.31M	1.77M
Interest Expense	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	2.66M	1.9M	n/a	2K	4K	6K	7K	7K	8K	9K	10K	3K
Selling & Marketing Expenses	n/a	n/a	n/a	-116K	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Cost & Expenses	94.54M	64.13M	123M	66.77M	59.52M	51.44M	49.25M	45.85M	42.74M	39.7M	36.72M	27.75M	72.74M	19.24M	15.44M	16.09M	6.14M	3.56M	2.31M	1.77M
Income Tax Expense	6.47M	-882K	1.55M	72.72K	10.52M	-99K	-3.41M	-7.02M	-5.29M	-3.8M	-189K	-3K	4K	7K	-27K	-920K	-1.24M	-1.01M	-639K	-456K
Shares Outstanding (Basic)	93.62M	96.62M	87.12M	86.68M	87.23M	85.95M	74.96M	71.97M	73.46M	71.01M	60.76M	58.38M	61.95M	61.93M	61.93M	61.93M	61.93M	61.93M	61.93M	61.93M
Shares Outstanding (Diluted)	93.62M	96.94M	87.12M	86.68M	87.23M	85.95M	74.96M	71.97M	73.46M	71.01M	60.76M	58.38M	61.95M	61.93M	61.93M	61.93M	61.93M	61.93M	61.93M	61.93M
EPS (Basic)	-0.7	0.38	-0.05	-0.72	-0.62	-0.54	-0.61	-0.49	-0.47	-0.48	-0.6	-0.48	-1.93	-0.31	-0.23	-0.25	-0.56	-0.05	-0.03	-0.02
EPS (Diluted)	-0.7	0.38	-0.05	-0.72	-0.62	-0.54	-0.61	-0.49	-0.47	-0.48	-0.6	-0.48	-1.93	-0.31	-0.23	-0.25	-0.56	-0.05	-0.03	-0.02
EBITDA	-64.57M	29.64M	-114.49M	-66.77M	-59.5M	-51.44M	-49.25M	-45.85M	-42.73M	-39.7M	-36.59M	-27.75M	-21.97M	-19.18M	-15.39M	-16.04M	-35.54M	-3.79M	-2.35M	-1.98M
EBIT	-65.33M	29.64M	-114.81M	-66.77M	-59.52M	-51.44M	-49.25M	-45.85M	-42.74M	-39.7M	-36.72M	-27.75M	-21.95M	-19.23M	-15.44M	-16.09M	-35.59M	-3.83M	-2.4M	-1.99M
Depreciation & Amortization	759K	n/a	408K	116K	103K	99K	92K	89K	180K	165K	133K	53K	5K	50K	49K	49K	49K	46K	46K	14K